An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

NCT02625090 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
42
Enrollment
INDUSTRY
Sponsor class

Stopped Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure

Conditions

Interventions

Sponsor

UCB Biopharma SRL